迈普医学
(301033)
| 流通市值：38.94亿 | | | 总市值：46.23亿 |
| 流通股本：5646.91万 | | | 总股本：6704.96万 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 249,228,235.32 | 157,777,674.14 | 73,703,893.55 | 278,442,127.39 |
| 营业收入 | 249,228,235.32 | 157,777,674.14 | 73,703,893.55 | 278,442,127.39 |
| 利息收入 | - | - | 0 | - |
| 已赚保费 | - | - | 0 | - |
| 手续费及佣金收入 | - | - | 0 | - |
| 二、营业总成本 | 170,015,989.07 | 107,860,363.58 | 48,479,325.85 | 202,578,024.19 |
| 营业成本 | 47,688,073.55 | 30,628,424.06 | 14,356,380.8 | 57,563,558.12 |
| 利息支出 | - | - | 0 | - |
| 手续费及佣金支出 | - | - | 0 | - |
| 退保金 | - | - | 0 | - |
| 赔付支出净额 | - | - | 0 | - |
| 提取保险合同准备金净额 | - | - | 0 | - |
| 保单红利支出 | - | - | 0 | - |
| 分保费用 | - | - | 0 | - |
| 税金及附加 | 4,645,903.4 | 3,086,711.34 | 1,448,604.63 | 5,209,252.99 |
| 销售费用 | 44,228,490.91 | 27,889,019.94 | 11,675,610.94 | 57,205,636.83 |
| 管理费用 | 49,001,203.54 | 30,344,696.2 | 14,110,660.44 | 56,832,710.86 |
| 研发费用 | 25,760,728.67 | 17,372,330.53 | 7,846,308.01 | 27,090,650.72 |
| 财务费用 | -1,308,411 | -1,460,818.49 | -958,238.97 | -1,323,785.33 |
| 其中:利息费用 | 18,522.03 | 15,548.61 | 10,356.64 | 904,084.36 |
| 其中:利息收入 | 1,293,322.68 | 1,058,225.55 | 799,326.97 | 2,050,272.24 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -123,542.42 | -446,766.21 | -594,552.73 | 151,575.36 |
| 加:投资收益 | 2,368,792.54 | 1,785,129.36 | 1,188,297.56 | 3,428,431.47 |
| 汇兑收益 | - | - | 0 | - |
| 资产处置收益 | 6,437.07 | - | - | 790.78 |
| 资产减值损失(新) | -128,571.35 | -9,077.79 | -29,560.99 | -69,976.92 |
| 信用减值损失(新) | 69,926.32 | 32,145.23 | -32,994.93 | -95,828.86 |
| 其他收益 | 7,575,651.64 | 5,590,659.4 | 2,779,303.07 | 12,442,950.53 |
| 四、营业利润 | 88,980,940.05 | 56,869,400.55 | 28,535,059.68 | 91,722,045.56 |
| 加:营业外收入 | 1,644,098.27 | 59,159.97 | 58,383.66 | 2,613,416.1 |
| 减:营业外支出 | 2,846,273.73 | 2,114,766.72 | 277,450.96 | 1,178,367.28 |
| 五、利润总额 | 87,778,764.59 | 54,813,793.8 | 28,315,992.38 | 93,157,094.38 |
| 减:所得税费用 | 11,924,727.75 | 7,514,651.1 | 4,153,685.38 | 14,302,864.15 |
| 六、净利润 | 75,854,036.84 | 47,299,142.7 | 24,162,307 | 78,854,230.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 75,854,036.84 | 47,299,142.7 | 24,162,307 | 78,854,230.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 75,854,036.84 | 47,299,142.7 | 24,162,307 | 78,854,230.23 |
| 扣除非经常损益后的净利润 | 72,791,913.75 | 45,996,448.89 | 22,924,937.92 | 68,113,273.78 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.15 | 0.71 | 0.37 | 1.2 |
| (二)稀释每股收益 | 1.14 | 0.71 | 0.36 | 1.2 |
| 八、其他综合收益 | 100,175.2 | 158,942.97 | 51,005.19 | 7,467.26 |
| 归属于母公司股东的其他综合收益 | 100,175.2 | 158,942.97 | 51,005.19 | 7,467.26 |
| 九、综合收益总额 | 75,954,212.04 | 47,458,085.67 | 24,213,312.19 | 78,861,697.49 |
| 归属于母公司股东的综合收益总额 | 75,954,212.04 | 47,458,085.67 | 24,213,312.19 | 78,861,697.49 |
| 公告日期 | 2025-10-24 | 2025-08-22 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |